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Objectives. Small diameter PTFE grafts are prone to thrombosis and intimal hyperplasia development. Heparin graft
coating has beneficial effects but also potential drawbacks. The purpose of this study was to evaluate the experimental
efficacy of PEG-hirudin/iloprost coated small caliber PTFE grafts.
Methods. Thirty-six femoro-popliteal ePTFE grafts (expanded polytetrafluoroethylene, diameter 4 mm) were inserted into
18 pigs. Grafts were randomised individually for each leg and grouped for 3 groups. Group I consisted of native ePTFE
grafts, group II were grafts coated with a polylactide polymer (PLA) without drugs and group III grafts were coated
with PLA containing a polyethylene glycol (PEG)-hirudin/iloprost combination. The follow-up period was 6 weeks. Patency
rates were calculated and development of pseudointima inside the grafts was noted. Thickness of intimal hyperplasia at the
distal anastomoses was measured using light microscopy.
Results. Patency rates for group I were 6/9 (67%), for group II 9/10 (90%) and 12/12 (100%) for group III. In groups I
and II there was a significant reduction of blood flow proximal to the graft at graft harvest, to 29 12 and 28 20 ml/min
respectively (both p< 0.01 versus preoperative value), whilst in group III blood flow, 99 21 ml/min, remained at the pre-
operative level. Subtotal stenosis due to development of pseudointima was noted in each of the native and PLA coated grafts
but not in group III grafts. Intimal hyperplasia at the distal anastomosis was lowest in group III.
Conclusions. The PEG-hirudin/iloprost coating of ePTFE prostheses effectively reduced pseudointima and intimal hyper-
plasia development and led to superior graft patency.
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It is generally accepted, that the primary choice for in-
frainguinal reconstructions is the autologous vein.1,2
However, in the absence of a suitable vein, a prosthetic
graft has to be inserted. Small calibre vascular pros-
theses are associated with high rates of graft failure
due to thrombosis and development of intimal hyper-
plasia.3,4 Particularly the prognosis of crural PTFE
grafts remains poor. In order to prevent early graft
failure, systemic anticoagulation using vitamin K
antagonists is commonly administered.5,6 Since the
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prostheses providing marginal flow rates are prone to
early graft thrombosis.7,8 Several approaches have
been developed in order to reduce the thrombogenic-
ity of graft surfaces.9e11 In the past, various efforts
were undertaken to facilitate endothel cell seeding
to enhance the thromboresistance.11 However the en-
dothel cell seeding procedure is cumbersome and
time consuming since the cells have to be harvested
from a patient’s vein, several weeks ahead of the def-
inite peripheral reconstruction.11,12 Alternatively pros-
thetic grafts can be bonded with antithrombotic drugs
like heparin or dipyridamole.10,13 However the big-
gest drawback of the use of heparin remains the risk
of heparin-induced thrombocytopenia.14e16
A promising and safe alternative to heparin with
even higher anticoagulative properties represents
the combination of hirudin and iloprost.17 Hirudin isrved.
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and clot-bound thrombin. It is not dependent, un-
like heparin, on antihrombin III. Iloprost acts as a
strong inhibitor of thrombocyte activation and aggre-
gation.17,18 In addition it has a strong vasodilator
effect which could be particularly important for pe-
ripheral grafts with poor runoff.19,20 The use of a poly-
lactide polymer coating as a drug carrier allows a safe
delivery of the anticoagulant drugs from the graft sur-
face to reduce the thrombogenicitiy of the prosthesis
during several weeks and months.
The PEG-hirudin/iloprost coating technology has
previously been shown to effectively reduce throm-
bogenicity of clinically used vascular prostheses in
vitro.21 We therefore intended to compare a PEG-
hirudin/iloprost coated prosthesis against an uncoat-
ed and a graft with polylactide sealing in a randomized
fashion in an animal experimental setting. We used
a porcine model, since pigs produce a reliable intimal
hyperplastic response and because the coagulation
system of the pig resembles the human system.22e24
Material and Methods
Graft coating
Eight centimeter long segments of 4 mm diameter
ePTFE grafts were coated under sterile conditions
with a polylactide polymer (PLA, MW 30 kDa,
Resomer R203, Boehringer Ingelheim, Ingelheim,
Germany) as described previously.17 An 8% PLA solu-
tion was used, containing 5% polyethylene glycol
(PEG) hirudin (lepirudin, Aventis Pharma GmbH,
Germany) and 1% iloprost (Ilomedin, Schering AG,
Berlin, Germany). The grafts were dip-coated twice
into the solution to achieve a homogenous coating
and then dried and sterile packed. The detailed re-
lease characteristics of PEG-hirudin and iloprost
from the coating have been described elsewhere.21 Af-
ter an initial accelerated release of both drugs during
the first 48 h, a slower and continuous release follows
over a period greater than 3 months. After 90 days
approximately 60% of the PEG-hirudin and 10% of
the iloprost were released.
Animals, surgical and randomization procedures
Thirty-six 4-mm ePTFE grafts were implanted in eigh-
teen female domestic pigs (25-30 kg, age 10 to 16
weeks, German Landrace). Since each animal received
two grafts, each side was randomised using closed en-
velopes. Two animals died during the course of the
experiments, one due to an infected port system andone due to malignant hyperthermia (each ePTFE/
PLA combination). One infected graft (ePTFE) was ex-
cluded from the study. Eventually, group I consisted
of native ePTFE grafts (n¼ 9), group II comprised
PLA coated ePTFE grafts (n¼ 10) and group III PLA
containing PEG-hirudin/iloprost (n¼ 12).
After intramuscular sedation with 4 mg/kg aza-
piron (Stresnil, Janssen, Germany), 10 mg/kg ket-
amine (Ursotamin, Serumwerk Bernburg, Germany)
and 0.05 mg/kg atropine (B.Braun AG Melsungen,
Germany), a 20-gauge needle was placed in an ear
vein. General anaesthesia was maintained after endo-
tracheal intubation with isoflurane (Baxter AG, Mu¨n-
chen, Germany) and oxygen. Antibiotic prophylaxis
was provided with 1.2 g amoxicillin (Augmentan,
GlaxoSmithKline GmbH, Mu¨nchen, Germany) intra-
venously during surgery and for two doses after sur-
gery. A port system for intravenous administration of
drugs and blood sampling was placed into the first 5
animals. This procedure was discontinued after one
animal died due to an infection of the port system.
Longitudinal incisions (12 cm) were made in both
hind limb groins. The femoral artery was dissected
free from the inguinal ligament to the first segment
of the popliteal artery. The deep femoral artery was li-
gated and dissected out. The baseline flow was mea-
sured by means of an ultrasonic flow meter (T206,
Transonic Systems, Ithaca, USA). Following systemic
heparinisation with 300 IE/kg heparin the common
femoral artery was clamped. The proximal anastomo-
sis was created end-to-end using a 7-0 polyproylene
(Prolene, Ethicon, Germany) running suture. The dis-
tal anastomosis was sutured to the distal superficial
femoral artery in an end-to-side fashion using a
7-0 Prolene running suture. After restoring blood
flow, the flow rate was measured again to confirm
patency. The wounds were closed subcutaneously
with a running 4-0 polyglactin 910 (Vicryl, Ethicon,
Germany) suture and a 4-0 poliglecaprone 25 (Mono-
cryl, Ethicon, Norderstedt, Germany) suture for the
skin. All animals received 100 mg aspirin/day (ASS
100, Ratiopharm, Germany). The study protocol was
approved by the local ethical committee. Animal
care complied with the ‘‘Principles of Laboratory
Animal Care’’ and the Guide for the Care and Use
of Laboratory Animals’’ (NIH Publication No. 80-23,
revised 1985).
Follow-up and termination
Graft patency was confirmed once a week and on the
day of the harvest using color-coded duplex sonogra-
phy under sedation, as described previously.Eur J Vasc Endovasc Surg Vol 32, October 2006
420 M. Heise et al.Six weeks after implantation the grafts were re-
moved. Following induction of general anesthesia,
the abdomen was opened using a midline incision
and the distal aorta was dissected free. Longitudinal
incisions in each hind limb groin were made and the
grafts were identified. Both the proximal as well as
the distal anastomoses were dissected free. In patent
grafts, blood flow was measured in the common fem-
oral artery just above the proximal anastomosis. After
systemic heparinisation the distal aorta was ligated
and a perfusion cannula inserted. For fixation of the
femoral artery and the ePTFE graft a 4% formalin
solution was injected into the distal aorta applying
a perfusion pressure of 100 mmHg. The graft and
the adjacent anastomoses were excised and stored
in 4% formalin solution.
Specimen processing and morphometric analysis
Only patent grafts were included in the histological
analyses. The specimens were dehydrated to 100% eth-
anol and were paraffin embedded. Serial longitudinal
5 mm sections were analyzed until the central anasto-
mostic area containing the maximum graft diameter
was identified. The representative sectionswere depar-
affinized in xylene and rehydrated.Afterhydration, the
slides were stainedwith the Verhoeff’s elastic stain and
vanGieson’s counterstain technique to highlight the in-
ternal elastic lamina. In addition, haematoxylin and eo-
sin stained slideswere produced in a standardmanner.
Sectionswere analysedwithdigital planimetry (ImageJ
1.3, NIH, USA). The neointima of the heel and hood
portions was measured as the distance between the in-
ternal elastic lamina and the lumen at four evenly
spaced locations (distance 0.3 mm) starting at the pros-
theses level (location #1) and ending on the regular en-
dothelial cell layer without significant neointimal
thickening (location #4) (Fig. 1).
Clinical chemistry aswell as hematologic and hemo-
static laboratory valuesweremeasuredbefore the oper-
ation, on each follow-up examination and before graft
removal. The activated partial thromboplastin time
(aPTT) was of particular interest, since this parameter
would reveal a systemic release of PEG-hirudin.
Statistical analysis
Data were expressed as mean SD. The patency
was analysed by means of a chi-square analysis. Dif-
ferences between flow rates within the same groups
were calculated using the Wilcoxon test, between the
groups using the Mann-Whitney U test and the
Kruskal-Wallis test. Differences in laboratory valuesEur J Vasc Endovasc Surg Vol 32, October 2006were calculated after stratification of groups into
antithrombotic and non-antithrombotic coating. P-
Values <0.05 were considered statistically significant.
Results
Patency and flowrate measurements
In the native ePTFE graft group I (n¼ 9) three grafts oc-
cluded during the six weeks follow up period (patency
rate 67%) while in group II (PLA, n¼ 10) one graft was
closed, corresponding to a patency rate of 90%. How-
ever in group III (PEG-hirudin/iloprost, n¼ 12) no
graft occlusion was seen (c2 p¼ 0.07). While the base-
line flow rates before graft implantationwere compara-
ble for all groups, a significant difference was seen
between groups I-II and III at the time of removal
(Table 1). Flow rates in the ePTFE and PLA group
Fig. 1. Longitudinal section of the distal anastomosis. Inti-
mal hyperplasia primarily developed at the anastomosis
hood and heel regions. The reaction on the arterial floor
(bottom) was mild. Numbers indicate measurement loca-
tions of neointimal thickness. (Verhoeff van Giesson stain,
original magnification 1.6).
Table 1. Comparison of flowrates (ml/min) measured at the
common femoral artery immediately after graft implantation and
before graft removal after 6 weeks. The significant decrease of
the volumetric flowrates in groups I-II corresponded to a marked
development of pseudointima, which was not seen in group III
Group n Baseline
flowrates
Removal
flowrates
p-value
Group I
(uncoated ePTFE)
6 104 9 29 12 <.01
Group II (PLA coated) 9 105 10 28 20 <.01
Group III
(PEG-hirudin/ilo-prost
coated)
12 106 8 99 21 n.s.
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rates, while the flow rates of the PEG-hirudin/iloprost
group showed no differences between implantation
and removal. The significant decline of the flow rates
of groups I and II corresponded to a marked develop-
ment of pseudointima leading to a circumferential
stenosis of the graft lumen (Fig. 2A). Conversely only
a thin and transparent layer of pseudointima was
seen in group III grafts (Figs. 2B, 3).
Histology and morphometric analysis
Intimal hyperplasia (IH) was defined as the thickness
of the layer between vessel lumen and internal elastic
lamina. The results are depicted in Table 2. In all graft
types the intimal hyperplasia decreased gradually
with increasing distance from the anastomoses. IH de-
velopment was more prominent in the anastomotic
hood areas than in the heel regions. In all cases IH de-
velopment was stronger in grafts without antithrom-
botic coating, compared to the PEG-hirudin/iloprost
coating group. However, statistical significant differ-
ences between the groups were limited to the mostcentrally located IH areas of the anastomotic hood
(#1 in Fig. 1).
There were no significant differences in the clinical
chemistry and hematological or hemostatic values
during the course of the experiments (data not
shown). Especially the aPTT values in animals with
PEG-hirudin/iloprost coated grafts (31 6 s) and
without antithrombogenic coating (30 5 s) showed
no significant difference.
Discussion
Small calibre PTFE grafts with low mean flow rates
generally have a high risk of graft failure due to tech-
nical problems and the high thrombogenicity of
PTFE.1,7 In order to reduce the thrombogenicity of
the PTFE/graft interface several approaches exist.25
One potentially promising approach to reduce the
thrombogenicity of PTFE grafts represents the phar-
macological modification of the blood/graft interface.
Anticoagulant drugs to be considered in this regard
comprise heparin, dipyridamole and hirudin.10,17,26
The first clinical trials using heparin bonded PTFE
grafts were promising, although the differenceFig. 2. Comparison of the distal anastomoses of an uncoated (A) versus a PEG-hirudin/iloprost coated (B) ePTFE graft. A
marked pseudointima, resulting in a subtotal stenosis, developed in all uncoated/PLA coated prostheses (n¼ 19), while
only a thin layer was seen in antithrombotic coated grafts (n¼ 12). denotes distal femoral/popliteal artery. ePTFE -
expanded polytetrafluoroethylene. (Verhoeff van Giesson stain, original magnification 1.6).Eur J Vasc Endovasc Surg Vol 32, October 2006
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tistically not significant after 5 years.13,27,28
Use of a heparinized graft has some drawbacks
since the antithrombotic action of heparin is depen-
dent on circulating cofactors (Antithrombin III) and
is not effective against clot-bound thrombin.26 Another
Fig. 3. Scanning electron micrographs of longitudinally sec-
tioned PTFE grafts (luminal view), removed after 6 weeks
(A¼ uncoated PTFE 200, B¼ PEG-hirudin/iloprost coated
PTFE 50, inset 500). While the uncoated graft (A) was
loaded with fibrin clots and debris, the antithombogetic
coated surface (B) showed only a thin layer of pseudointima
with few blood cells.Eur J Vasc Endovasc Surg Vol 32, October 2006real concern is the occurrence of heparin-induced
thrombocytopenia. Heparin, released from the coated
graft, could sensitise patients with this disease result-
ing in bleeding and thrombo-embolic complications.
The incidence of this potential harmful disease among
vascular surgical patients ranges between 2% and
21%.14e16 The high incidence is probably due to the
frequent exposure of these patients to heparin. There
is a report of a patient, who developed a diffuse
thrombosis following placement of a heparin-coated
coronary stent.29 Since the immunogenic surface is
much greater in long segments of 6 or 8 mm PTFE
grafts, compared to a small coronary stent, the poten-
tial risk would appear to be higher in patients requir-
ing peripheral reconstructions. In affected cases an
immediate graft removal with potential limb loss
would be mandatory.
A promising and safe alternative for the heparin
coating represents the combination of hirudin and
iloprost, used with a coating technique that gra-
dually releases the drugs into the graft lumen. We
therefore selected a polylactide polymer coating tech-
nology, that has been used for several other projects
in cardiovascular and orthopaedic medicine.17,21,30
The hydrolytic step-by-step degradation of the poly-
mer allows a continuous release of drugs over weeks
and several months, depending on the thickness of
the coating layer. Although the observation time of
this study was limited to 6 weeks, the beneficial
effect of the drug coating could be expected to last
at least for 3 months.21 The rationale of using PEG-
hirudin together with iloprost was the combination
of a thrombin inhibitor with a strong antiplatelet
drug. The PEG-hirudin/iloprost combination has
been used successfully for coating of coronary stents
in animal experiments.31 Hirudin is a specific and
highly potent inhibitor of thrombin. It is able to
inhibit both clot-bound and soluble thrombin. The re-
combinant form was found to be very effective for
prevention of arterial thrombosis in animal models.32
When conjugated with polyethylene glycol (PEG) the
duration of action is prolonged significantly.33
In a recent study the antithrombotic superiority of
hirudin compared to heparin was clearly demon-
strated.34 Since thrombin acts as a potent mitogenTable 2. Effect of antithrombotic coating of ePTFE prostheses on the development of intimal hyperplasia (mm) at the distal anastomosis
of femoro-popliteal grafts in pigs. ePTFE[ expanded polytetrafluoroethylene
Group n Hood #1 Hood #2 Hood #3 Hood #4 Heel #1 Heel #2 Heel #3 Heel #4
ePTFE 7 0.48 0.1 0.25 0.1 0.19 0.1 0.15 0.1 0.37 0.1 0.28 0.1 0.21 0.1 0.15 0.1
PLA coated ePTFE 7 0.47 0.1 0.36 0.1 0.30 0.1 0.22 0.1 0.34 0.1 0.29 0.1 0.20 0.2 0.14 0.1
PEG-hirudin/iloprost coating 11 0.20 0.1 0.16 0.1 0.13 0.1 0.11 0.1 0.18 0.1 0.14 0.1 0.12 0.1 0.10 0.1
p-value <0.05 n.s. n.s. n.s. n.s. n.s. n.s. n.s.
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neointimal thickening.35
The copartner of hirudin, iloprost is a prostaglandin
I2 analogue which as been shown to effectively inhibit
platelet activation and aggregation.18 It additionally
has vasodilatator effects, which are particularly im-
portant for peripheral reconstructions with poor run-
off vessels. After arterial application iloprost induces
a peripheral vasodilatation, thus reducing the peri-
pheral resistance and impedance, leading to an
enhanced blood flow through the grafts.19,20 Both
drugs bear antiproliferative capabilities and it has
previously been shown that they had beneficial effects
regarding neointimal development.31,36
The present study clearly demonstrated the benefit
of aPTFEcoatingwithaPEG-hirudin/iloprost bonding.
In order to create realistic and disadvantageous condi-
tions,weused small ePTFE grafts, implanted into a rela-
tively low flow area of the porcine hind limb. The
measured blood flow of 100 ml/min resembles that of
crural arteries.19 The use of a distal end-side anastomo-
sis was chosen to induce a flow pattern, which is prone
to neointimal hyperplasia development.37,38
All of the implanted antithrombotic coated grafts
were patent and showed only very small amounts
of pseudointima development. The remaining grafts
developed a marked pseudointima leading to
a significant graft stenosis which corresponded to
a significant decrease of the flow rates, which even-
tually contributed to graft failure. The small layer
which was seen in antithrombotic coated grafts
was covering the entire graft surface. We hypothe-
sized that the small neocoating was responsible for
a decreased surface thrombogenesis of the ePTFE
prostheses.
Despite differences in patency and development of
pseudointima, which were ascribed to a reduced
thrombogenicity of the grafts, we additionally ob-
served a considerable reduction of intimal hyperpla-
sia development inside the distal anastomoses. In
addition to enhanced flow characteristics, this was at-
tributed to the antiproliferative properties of hirudin
and iloprost.31,35
We did not observe local or systemic effects of the
graft coating. The coating did not influence the graft
healing into the subcutaneous tissue and we did not
observe peri-graft reaction. The locally released drugs
did not impair the systemic coagulation. This sup-
ports the hypothesis, that the anti-thrombotic effect
of the eluted drugs is essentially limited to the pros-
thesis surface. The available data suggest that the
coating of ePTFE grafts with a PEG-hirudin/iloprost
eluting polymer meets the safety requirements for
peripheral reconstructions.In conclusion the PEG-hirudin/iloprost coating of
PTFE prostheses represents a promising approach
for improvement of small PTFE grafts and should be
further investigated in a randomised clinical trial.
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